NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | West Pharmaceuticals Expands Dublin Facility for Injectable Therapies | Lilly to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Disorder Treatments | Vertex Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference | Vanda Pharmaceuticals Becomes Founding Partner of Capital One Arena | Tonix Pharmaceuticals Licenses Lyme Disease Antibody for Lyme Disease Prevention | AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder | Vertex Pharmaceuticals Stock: Earnings and Revenue Analysis | NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | West Pharmaceuticals Expands Dublin Facility for Injectable Therapies | Lilly to Acquire Centessa Pharmaceuticals to Advance Sleep-Wake Disorder Treatments | Vertex Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference | Vanda Pharmaceuticals Becomes Founding Partner of Capital One Arena | Tonix Pharmaceuticals Licenses Lyme Disease Antibody for Lyme Disease Prevention | AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder | Vertex Pharmaceuticals Stock: Earnings and Revenue Analysis
After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S. commercial availability of NEREUS™ (tradipitant), offering a modern, targeted approach to prevent...
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
West Pharmaceutical Services has expanded its facility in Damastown, Dublin, to meet the growing demand for injectable therapies, including those for diabetes and obesity. This expansion aims to enhance the company's contract services and g...
Iraqi militia says will release abducted U.S. journalist, adding that she must leave Iraq immediately
Eli Lilly and Company is set to acquire Centessa Pharmaceuticals for a potential total of $7.8 billion. This acquisition aims to advance treatments for sleep-wake disorders by leveraging Centessa's orexin receptor 2 (OX2R) agonists, which h...
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will participate in Citi’s 2025 Global Healthcare Conference on December 3, 2025. CFO Charlie Wagner and CSO David Altshuler will engage in a fireside chat at 9:00 a.m. ET. A live webcast w...
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
Monumental Sports & Entertainment (MSE) has announced Vanda Pharmaceuticals as a Founding Partner for Capital One Arena. This multi-year agreement includes naming rights for the Monumental Sports Network (MNMT) broadcast studio and extensiv...
Monumental Sports & Entertainment Taps D.C.’s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
Tonix Pharmaceuticals has licensed TNX-4800, a monoclonal antibody, from UMass Chan Medical School for the prevention of Lyme disease. This single-dose prophylactic aims to provide seasonal protection against the disease.
UMass Chan licenses monoclonal antibody for seasonal prevention of Lyme disease to Tonix Pharmaceuticals
AbbVie (NYSE: ABBV) has acquired Gilgamesh Pharmaceuticals' Bretisilocin, a novel investigational therapy for major depressive disorder (MDD), for up to $1.2 billion. This acquisition significantly expands AbbVie's psychiatry pipeline and u...
AbbVie targets psychedelic-based depression drug market with $1.2 billion deal
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing to announce its latest earnings. Investors are keen to understand how the stock will react, considering its historical performance and recent financial results.
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (VRTX) reported a 12% increase in total revenue for the second quarter of 2025, reaching $2.96 billion. This growth was fueled by strong performance in cystic fibrosis (CF) therapies and the successful launches of new...
Vertex Reports Second Quarter 2025 Financial Results
President Trump has announced proposals for new tariffs on copper and pharmaceuticals, potentially reshaping the trade landscape. These measures could significantly impact various industries and consumer prices.
Vanda Pharmaceuticals Inc. (VNDA) is set to participate in the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on May 21, 2025. This event provides an opportunity for Vanda to engage with investors and discuss advancements in neur...
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
Roche, a Swiss pharmaceutical giant, is investing $50 billion in the United States over the next five years to expand its research, development, and manufacturing capabilities. This significant investment aims to create over 12,000 new jobs...
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
Bayer AG's stock has shown minor gains recently, but the broader picture reveals significant pressure. This article recaps the latest performance data, financial results, and analyst outlooks compiled by Yanuki using the latest trends and d...
Recursion Pharmaceuticals (often associated with the ticker RXRX) has announced a significant step in its clinical development pipeline: the first patient has been dosed in its early-stage clinical trial targeting B-cell lymphomas. This mil...